Progyny EPS Outperforms, Revenue Dips in Q2
Revenue of $304.1 million met management's expectations. Adjusted EPS of $0.43 outperformed management's guidance.
Why Progyny Stock Dropped Today
Progyny missed analysts' revenue expectations for the second quarter by a tiny margin. Making matters worse, the company cut sales growth guidance from 15% to 8.5% for 2024.
Progyny, Inc. (PGNY) Q2 2024 Earnings Call Transcript
Progyny, Inc. (PGNY) Q2 2024 Earnings Call Transcript
Progyny (PGNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Progyny (PGNY) Beats Q2 Earnings Estimates
Progyny (PGNY) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.15 per share a year ago.
Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore
Progyny finds itself in an industry enjoying numerous secular tailwinds that they are well-positioned to capitalize on. The company reported Q1'24 on the 9th of May, with the stock plummeting around 15% after reporting a revenue miss. This presents an attractive entry point, with a conservatively estimated 49-76% upside.
Progyny: No Change To Long-Term Outlook
PGNY experienced a revenue miss in 1Q24 due to weak utilization. Historical data shows that IVF demand has been resilient, with strong rebounds following economic downturns. Leading indicators suggest that utilization rates are already improving, and demand remains solid, indicating potential for growth acceleration in the coming quarters.
Progyny's board approves another $100 million stock buyback
The board of Progyny PGNY, -2.62% has approved a $100 million share-repurchase authorization, its second this year.
